Asian Spectator


The Times

.

AIM Vaccine’s 13-valent pneumonia conjugate vaccine obtained Production license

Application for drug marketing registration duly submitted Super heavyweight items are expected to drive performance soaring

HONG KONG SAR - Media OutReach Newswire – 1 November 2024 - AIM Vaccine (06660.HK) announced on 1st November that the application for drug marketing registration of the Company's independently developed 13-valent pneumonia conjugate vaccine has been submitted to the National Medical Products Administration.

Magazine

Compressed Air Pipe and Fittings: What Every Australian Industrial Facility Needs to Know

Compressed air is the fourth utility of modern industry, right alongside electricity, gas, and water. Yet despite its critical role in powering everything from pneumatic tools to automated productio...

Common Risks Hidden in Commercial Lease Agreements

Commercial leases are often longer and more complex than tenants expect, and the fine print can carry significant financial and operational consequences over the years that follow. Many business own...

Corporate Secretarial Services in Singapore: Annual Compliance, Key Filings, and Common Mistake

Annual compliance in Singapore should not be treated as a once-a-year administrative event. It is an ongoing governance system that depends on accurate records, timely filings, disciplined approvals...

hacklink hack forum hacklink film izle hacklink z-librarytelegram webroyalbet girişjojobetjojobetPalazzobetcratosroyalbetcasino siteleriagen bolatelegram下载Meritkingzlibrary.jojobetสล็อตสล็อตjojobetjojobetcasibomnakitbahisnakitbahisnakitbahisholiganbetjojobetnakitbahisjojobet